


Comparison energy transfer  
Tixel vs. IPL\*



\* source: IOVS journal (March 2015):  
Prospective Trial of Intense Pulsed Light  
for the Treatment of Meibomian  
Gland Dysfunction



Novoxel® GmbH

Gatower Str. 124  
13595 Berlin, Germany

Tel.: +49 (0) 30 - 54 81 11 95  
Fax: +49 (0) 30 - 54 81 69 51

Email: info@novoxel.com  
www.novoxel.com

Customer Support

Tel.: +49 (0) 30 - 54 81 11 95  
Email: supportGmbH@novoxel.com



Non-radiation technology  
for safe dry eye treatment



Novoxel, Tixel, their logos and product designs are registered trademarks of Novoxel Ltd.

Product specifications are subject to change without notice.  
Products are not for sale in the US and Canada.  
Patented in USA, Israel, Japan; Pending in EU, South Korea and China.

## What is „Tixel C“ ?

- A novel non-ablative fractional system powered by Novoxel's patented titanium tip technology.
- „Tixel C“ employs direct heat and is radiation-free.



## Why „Tixel C“ ?


- Non-radiation technology – safer for retina
- Controlled direct surface heating by conduction
- Simultaneous heating and mechanical compression directly on glands
- Precise small dimensions tip, well defined locus heating
- Significantly reduced energy transfer compared to IPL
- Sterile tip prevents cross contamination of treated sites
- Superior and lower eye lids can be treated safely
- Quick (20 pulses, less than 1 minute per eye)




## Improvement of NBUT & OSDI after „Tixel C“

source: Vallmedic Vision, Andorra  
77 patient study

### Improvement of NBUT after Tixel treatment P < 0.05




Before treatment



Non invasive first  
Breakup time  
(NIF-BUT): 3,8 sec

After 2 treatments



Non invasive average  
Breakup time  
(NIAvg-BUT): 7,6 sec

### Improvement of OSDI-results after treatment with Tixel (% of patients)

